TCT 2019: IDEAL LM Inconclusive, While Onyx ONE Boosts Polymer-Based DES

Data from two late-breaking drug-eluting stent trials, presented on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco, prompted mixed reactions from interventional cardiologists.

Skyscrapers in San Francisco at night - Image
The Transcatheter Cardiovascular Therapeutics conference is held in San Francisco from 24 September to 29 September • Source: shutterstock.com

Results of the IDEAL LM trial showed patients with left main coronary artery disease treated with Boston Scientific Corp.'s Synergy everolimus-eluting platinum-chromium stent with a biodegradable polymer fared equally well with short-duration dual antiplatelet therapy (DAPT) as patients treated with Abbott Laboratories Inc.'s Xience everolimus-eluting cobalt-chromium stent and a standard 12-month course of antiplatelet therapy.

Robert-Jan Van Geuns, from Erasmus Medical Center in Rotterdam, reported the results on 26 September at Transcatheter Cardiovascular Therapeutics meeting...

More from Clinical Trials

More from R&D